McAllister IL, et al. - Researchers evaluated 58 candidates with macular edema caused by central retinal vein occlusion (CRVO) to ascertain the 2-year efficiency of intravitreal ranibizumab with a laser-induced chorioretinal anastomosis (L-CRA) vs ranibizumab alone. They observed a mean number of injections from month 7 to month 24, 3.2 in the combination group and 7.1 in the ranibizumab alone group indicating a significantly reduced number of ranibizumab injections requirement in case of an L-CRA for macular edema caused by CRVO.